A Look Inside the Toolbox for BRAF-Mutant Metastatic Melanoma

Podcast

In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.

In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, a medical oncologist and chief of the Melanoma Service at Memorial Sloan Kettering Cancer Center in New York, New York, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.

During the Physician’s Education Resource® 18th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® held in January 2022, Postow spoke to a room of peers about this topic. His talk focused on the past, present, and future of BRAF-directed treatment. During the podcast discussion with host, Nichole Tucker of Targeted Oncology™, the discussion was expanding to dive into topics like; the efficacy of FDA-approve BRAF targeted therapies, the most recent FDA approval and its impact, exploring approved agents in new treatment settings, and other key druggable targets in melanoma.

During the talk, Postow also touches on the main clinical questions that oncologists still have about treating patients with BRAF-mutant melanoma and what research is aiming to provide answers in the near future.

Recent Videos
Related Content